Companies: 10,795·Total market cap: $144.5T
Fresh Tracks Therapeutics, Inc.

Fresh Tracks Therapeutics, Inc.

FRTXNASDAQHealthcare
$0.94
$-0.01(-0.53%)
Market Cap$5585045
P/E Ratio—
52W High$1.0325
52W Low$0.03
SEC Filings

Fresh Tracks Therapeutics, Inc. (FRTX) SEC Filings & 10-K Annual Reports

SEC EDGAR regulatory submissions (10-K, 10-Q, 8-K), latest forms, and full filing history — quick links to financials and earnings below.

SEC EDGAR · data.sec.gov · CIK 0000819050 · FRTX · NASDAQ · as of Jun 9, 2026

Filing snapshot

1,000+
Total Filings
4
Latest Form
2024-06-11
Most Recent
1993
Filing Since
FinancialsEarningsView All on EDGAR

Source: SEC EDGAR (data.sec.gov) · CIK 0000819050 · Updated hourly · Not investment advice

Latest Annual Report

10-K · Annual ReportFY
Filed Date
2024-03-15
Fiscal Year End
Mar 15, 2024
Accession No.
0001628280-24-011460
Primary Document
frtx-20231231.htm
View on SEC EDGARDownload PDFFiling Index
Source: data.sec.gov · CIK 0000819050 · Accession 0001628280-24-011460

Latest Key Filings

10-QQuarterly Report
10-Q
2023-11-13
View 10-Q on SEC
8-KCurrent Report
8-K
2024-03-07Material Event
View 8-K on SEC
Form 4Insider Activity
Ownership Change Disclosures

Executive & director trade disclosures. Full buy/sell sentiment analysis on the dedicated tab.

View Insider Trades Tab

SEC Filing History

Hide Form 4 / 144
SC 13DActivist Ownership Report
SCHEDULE 13D
2024-05-08
View
15-12G15-12G
15-12G
2024-03-18
View
10-KAnnual Report
10-K
2024-03-15
View
8-KCurrent Report
8-K
2024-03-07
View
8-KCurrent Report
8-K
2024-02-16
View
DEFA14AProxy Statement (Additional)
DEFA14A
2024-02-14
View
SC 13G/ABeneficial Ownership Report (Amended)
AMENDMENT NO. 1 TO SCHEDULE 13G
2024-01-18
View
DEF 14AProxy Statement
DEF 14A
2024-01-17
View
DEFA14AProxy Statement (Additional)
DEFA14A
2024-01-17
View
PRE 14APRE 14A
PRE 14A
2024-01-05
View
8-KCurrent Report
8-K
2024-01-03
View
S-8 POSS-8 POS
S-8 POS
2023-12-28
View
S-8 POSS-8 POS
S-8 POS
2023-12-28
View
S-8 POSS-8 POS
S-8 POS
2023-12-28
View
S-8 POSS-8 POS
S-8 POS
2023-12-28
View
Showing 1–15 of 624 filingsForm 4 / 144 hidden· 1000 total in EDGAR

About SEC Filings & 10-K Annual Reports

Data source: SEC EDGAR (data.sec.gov)  |  Updated: Hourly  |  CIK: 0000819050  |  Exchange: NASDAQ · Healthcare

Fresh Tracks Therapeutics, Inc. (NASDAQ: FRTX) has submitted 1,000+ documents to the U.S. Securities and Exchange Commission (SEC) since its IPO in 1993. As a Healthcare sector company with CIK 0000819050, all filings are publicly accessible via the EDGAR database at no cost.

The annual 10-K report is Fresh Tracks Therapeutics, Inc.'s most comprehensive regulatory disclosure. The most recent Fresh Tracks Therapeutics, Inc. 10-K was filed on 2024-03-15 for fiscal year ending 2024. Historical FRTX 10-K annual reports are available from 2008 through 2024.

Investors researching Fresh Tracks Therapeutics, Inc. SEC filings can access 10-K annual reports, quarterly 10-Q reports, material event 8-K filings, and proxy statements directly from the links above. All documents are sourced from the official SEC EDGAR system.

Source: SEC EDGAR · data.sec.gov · SEC Form 10-K · SEC Form 10-Q · SEC Form 8-K2026-06-09
Related Companies SEC Filings — Healthcare
TECX SEC Filings →NEUP SEC Filings →ENTO SEC Filings →TNFA SEC Filings →TCDA SEC Filings →XBIO SEC Filings →BVXV SEC Filings →APTO SEC Filings →
→ FRTX Financials→ FRTX Earnings→ FRTX Insider Trades

Frequently Asked Questions

FRTX SEC Filings · 8 questions

Fresh Tracks Therapeutics, Inc. (FRTX) SEC filings are publicly available on this page and on the official SEC EDGAR database at sec.gov. You can browse all 1,000+ filings and access original documents at no cost. Fresh Tracks Therapeutics, Inc.'s CIK is 0000819050.

FRTX SEC filingsFresh Tracks Therapeutics, Inc. SEC documentsfind FRTX 10-K